|
1,966
|
| 15363 |
HSC (CD150+CD48-CD41-Lin-)
|
|
interacts (colocalizes) with
|
sinusoidal endothelium (MECA-32+)
|
in mobilized spleen (62% of the cells)
|
in vivo
|
| 28832 |
HSC (CD150+CD48-CD41-Lin-)
|
|
interacts (colocalizes) with
|
sinusoidal endothelium (MECA-32+)
|
in bone marrow ( about 57% of the cells)
|
in vivo
|
| 28836 |
HSC (CD150+CD48-CD41-Lin-)
|
|
interacts (colocalizes) with
|
endosteum
|
in bone marrow ( about 14% of the cells)
|
in vivo
|
|
15989959
|
|
2,102
|
| 17127 |
Vcam1
|
|
interacts (colocalizes) with
|
Itga4
|
|
|
|
16151515
|
|
2,140
|
| 35937 |
dormant-HSC (LRC, Kit+)
|
|
interacts (colocalizes) with
|
endosteum
|
|
in vivo
|
|
19062086
|
|
2,569
|
| 24849 |
osteoblast (ALP+Thpo+)
|
|
increases_quantity of
|
Thpo
|
|
in vivo
|
| 24884 |
HSC (CD34-Mpl+KSL)
|
|
increases_quantity of
|
Mpl
|
|
in vivo
|
| 25887 |
HSC (CD34-Mpl+KSL)
|
|
interacts (colocalizes) with
|
osteoblast (ALP+Thpo+)
|
|
in vivo
|
|
18371409
|
|
2,614
|
| 24838 |
Mpl
|
|
interacts (colocalizes) with
|
Thpo
|
|
|
| 24839 |
TPO/MPL signaling
|
|
increases_quantity of
|
megakaryocyte
|
|
|
| 24840 |
Mpl
|
|
increases_activity of
|
TPO/MPL signaling
|
|
|
| 24841 |
Thpo
|
|
increases_activity of
|
TPO/MPL signaling
|
|
|
|
18371409
|
|
2,628
|
| 24961 |
HSC (Tie2+SP,KSL)
|
|
increases_quantity of
|
Tek
|
|
in vivo
|
| 24995 |
osteoblast (osteocalcin+)
|
|
increases_quantity of
|
Angpt1
|
|
in vivo
|
| 24998 |
Angpt1
|
|
interacts (colocalizes) with
|
Tek
|
in osteoblasts
|
in vivo
|
| 25038 |
Angpt1
|
|
increases_activity of
|
Tie2/Ang1 signaling
|
|
|
| 25040 |
Tek
|
|
increases_activity of
|
Tie2/Ang1 signaling
|
|
|
| 25042 |
HSC (Tie2+SP,KSL)
|
|
interacts (colocalizes) with
|
osteoblast (osteocalcin+)
|
|
in vivo
|
|
15260986
|
|
2,756
|
| 25502 |
SNO cell (N-cadherin+CD45-)
|
|
increases_expression of
|
Bmpr1a
|
but Bmpr1a is not expressed in HSCs
|
in vivo
|
| 25506 |
HSC (LRC)
|
|
interacts (colocalizes) with
|
SNO cell (N-cadherin+CD45-)
|
LT-HSCs are only attached to SNO cells that line the bone surface.
|
in vivo
|
| 25507 |
SNO cell (N-cadherin+CD45-)
|
|
increases_quantity of
|
Cdh2
|
|
in vivo
|
| 25527 |
SNO cell (N-cadherin+CD45-)
|
|
increases_quantity of
|
HSC (LRC)
|
|
in vivo
|
| 25596 |
Bmpr1a
|
|
increases_activity of
|
BMP signaling pathway
|
|
|
| 35823 |
HSC (N-cadherin+CD45+KSL)
|
|
interacts (colocalizes) with
|
SNO cell (N-cadherin+CD45-)
|
LT-HSCs are only attached to SNO cells that line the bone surface.
|
in vivo
|
| 37278 |
BMP signaling pathway
|
|
decreases_quantity of
|
SNO cell (N-cadherin+CD45-)
|
|
in vivo
|
| 37280 |
HSC (N-cadherin+CD45+KSL)
|
|
increases_quantity of
|
Cdh2
|
|
in vivo
|
|
14574412
|
|
2,761
|
| 25577 |
CAR cell
|
|
increases_quantity of
|
HSC (CD34-CD150+CD48-KSL)
|
|
in vivo
|
| 25584 |
CAR cell
|
|
increases_expression of
|
Cxcl12
|
|
in vivo
|
|
20850355
|
|
2,766
|
| 25616 |
Cxcl12
|
|
interacts (colocalizes) with
|
Cxcr4
|
|
|
| 25634 |
Cxcr4
|
|
increases_activity of
|
CXCL12/CXCR4 signaling
|
|
in vivo
|
| 25636 |
Cxcl12
|
|
increases_activity of
|
CXCL12/CXCR4 signaling
|
|
in vivo
|
| 25640 |
HSC (CD34-KSL)
|
|
increases_expression of
|
Cxcr4
|
compared to CD34+KSL progenitor cells
|
in vivo
|
| 25648 |
CAR cell
|
|
increases_quantity of
|
Cxcl12
|
|
in vivo
|
| 25666 |
HSC (CD150+CD48-CD41-)
|
|
interacts (colocalizes) with
|
CAR cell
|
|
in vivo
|
| 26811 |
HSC (Sca1+Kit+)
|
|
interacts (colocalizes) with
|
CAR cell
|
|
in vivo
|
|
17174120
|
|
2,819
|
| 25973 |
osteoblast (osteopontin+)
|
|
increases_quantity of
|
HSC (KSL)
|
in bone marrow; Notch1 activation is responsible for the stem cell expansion
|
in vitro
|
| 25977 |
Notch1
|
|
interacts (colocalizes) with
|
Jag1
|
|
|
| 25979 |
Notch1
|
|
increases_activity of
|
Notch signaling pathway
|
|
|
| 25980 |
Jag1
|
|
increases_activity of
|
Notch signaling pathway
|
|
|
| 25981 |
osteoblast (osteopontin+)
|
|
increases_quantity of
|
Jag1
|
|
|
| 25984 |
HSC (KSL)
|
|
increases_quantity of
|
Notch1
|
after PPR activation
|
in vivo
|
| 25990 |
PTH signaling
|
|
increases_quantity of
|
osteoblast (osteopontin+)
|
this results in Notch1-mediated expansion of HSC (KSL)
|
in vivo
|
|
14574413
|
|
2,834
|
| 26156 |
Dkk1
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
in HSC (KSL); in a non-cell autonomous manner
|
in vivo
|
| 26310 |
osteoblast
|
|
increases_expression of
|
Dkk1
|
if Dkk1 is under the control of the osteoblast-specific Col1alpha promoter
|
in vivo
|
|
18371452
|
|
2,856
|
| 26372 |
primary MSC-enriched cell (Alcam-Sca1+)
|
|
increases_expression of
|
Bmp4
|
|
|
|
20472830
|
|
2,862
|
| 26413 |
osteoblast (N-cadherin+)
|
|
increases_expression of
|
Ebf2
|
|
in vivo
|
| 26447 |
Ebf2
|
|
increases_activity of
|
Wnt signaling pathway
|
in HSC (KSL)
|
in vivo
|
| 26906 |
osteoblast (Ebf2+)
|
|
interacts (colocalizes) with
|
HSC (Sca1+)
|
|
in vivo
|
| 32512 |
osteoblast (Ebf2+)
|
|
increases_quantity of
|
Ebf2
|
|
in vivo
|
| 35935 |
osteoblast (Ebf2+)
|
|
increases_quantity of
|
HSC (KSL)
|
|
in vivo
|
|
20887955
|
|
2,878
|
| 26501 |
Wif1
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
|
|
| 26502 |
osteoblast
|
|
increases_expression of
|
Wif1
|
|
in vivo
|
| 26524 |
osteoblast
|
|
increases_expression of
|
Shh
|
in Wif1-overexpressing osteoblasts. Expression is down-regulated after 5-FU-treatment
|
in vivo
|
| 26528 |
HSC (CD34-KSL)
|
|
increases_expression of
|
Ptch1
|
in Wif1-overexpressing osteoblasts. Expression is down-regulated after 5-FU-treatment
|
in vivo
|
| 26531 |
Ptch1
|
|
interacts (colocalizes) with
|
Shh
|
|
|
| 26532 |
Ptch1
|
|
affects_activity of
|
smoothened signaling pathway
|
|
|
| 26533 |
Shh
|
|
affects_activity of
|
smoothened signaling pathway
|
|
|
| 26551 |
Wif1
|
|
increases_expression of
|
Ptch1
|
in HSC (CD34-KSL), if Wif1-overexpressing osteoblasts are present . Expression is down-regulated after 5-FU-treatment
|
in vivo
|
| 26552 |
Wif1
|
|
increases_expression of
|
Wnt3a
|
in HSC (CD34-KSL), if Wif1-overexpressing osteoblasts are present
|
in vivo
|
| 26566 |
Wnt3a
|
|
increases_activity of
|
Wnt signaling pathway
|
|
|
|
21652676
|
|
2,895
|
| 26590 |
osteoblast (osteopontin+)
|
|
increases_quantity of
|
Spp1
|
|
in vivo
|
|
15845900
|
|
2,896
|
| 26596 |
Spp1
|
|
interacts (colocalizes) with
|
Itgb1
|
|
in vitro
|
| 26597 |
HSC (CD34+CD38-)
|
|
increases_expression of
|
Itgb1
|
|
in vitro
|
|
15845900
|
|
2,899
|
| 26628 |
Itgb1
|
|
interacts (colocalizes) with
|
Itga4
|
in peripheral blood; which forms a heterodimer with beta1 integrin
|
in vivo
|
|
19417209
|
|
2,923
|
| 26773 |
HSC (CD34-KSL)
|
|
interacts (colocalizes) with
|
vascular endothelial cell (PECAM1+)
|
5 hours after transplantation. This association is dependent on ROS, which induces the expression of VCAM1
|
in vivo
|
| 26775 |
vascular endothelial cell (PECAM1+)
|
|
increases_quantity of
|
Vcam1
|
which is a major receptor of HSC (CD34-KSL)
|
in vivo
|
| 26778 |
Reactive oxygen species
|
|
increases_quantity of
|
Vcam1
|
in vascular endothelial cell (PECAM1)
|
in vivo
|
|
19797522
|
|
2,937
|
| 26833 |
mir-886-3p
|
|
decreases_expression of
|
Cxcl12
|
in BM stromal cells; by directly binding to the 3' UTR of Cxcl12 mRNA
|
in vitro
|
|
21179442
|
|
2,944
|
| 26851 |
response to hypoxia
|
|
decreases_quantity of
|
Reactive oxygen species
|
|
|
|
21670467
|
|
3,132
|
| 28863 |
SNO cell (N-cadherin+CD45-)
|
|
increases_quantity of
|
Cdh2
|
in c-Myc-deficient mice
|
in vivo
|
| 28865 |
HSC (KSL)
|
|
increases_quantity of
|
Cdh2
|
in c-Myc-deficient mice
|
in vivo
|
| 29408 |
Cdh2
|
|
interacts (colocalizes) with
|
Cdh2
|
|
|
|
15545632
|
|
3,158
|
| 29071 |
canonical Wnt signaling pathway
|
|
decreases_quantity of
|
Vcam1
|
in stromal cells
|
in vitro
|
|
18951693
|
|
3,182
|
| 29181 |
MSC (Nes+)
|
|
increases_quantity of
|
Nes
|
in contrast to vascular endothelial cells
|
|
| 29211 |
HSC (CD150+CD48-Lin-)
|
|
interacts (colocalizes) with
|
MSC (Nes+)
|
|
in vivo
|
| 29226 |
MSC (Nes+)
|
|
increases_quantity of
|
HSC (CD150+CD48-KSL)
|
in bone marrow, whereas the amount of HSC (CD150+CD48-KSL) in spleen decreases
|
in vivo
|
|
20703299
|
|
3,378
|
| 31430 |
Anxa2
|
|
increases_quantity of
|
HSC (CD150+CD48-CD41-KSL)
|
|
in vivo
|
| 31432 |
HSC (CD150+CD48-CD41-Lin-)
|
|
interacts (colocalizes) with
|
endosteum (Annexin2+)
|
|
in vivo
|
| 31433 |
endosteum (Annexin2+)
|
|
increases_expression of
|
Anxa2
|
|
in vivo
|
| 31436 |
Anxa2
|
|
increases_expression of
|
Cxcl12
|
in osteoblasts
|
|
| 31437 |
Anxa2
|
|
increases_expression of
|
Cxcr4
|
in HSC (CD150+CD48-CD41-KSL)
|
in vivo
|
| 31439 |
HSC (CD150+CD48-CD41-KSL)
|
|
increases_expression of
|
Cxcr4
|
|
in vivo
|
| 31441 |
Anxa2
|
|
interacts (colocalizes) with
|
Cxcl12
|
This interaction facilitates presentation of Cxcl12 to HSCs
|
in vitro
|
| 36495 |
endosteum (Annexin2+)
|
|
increases_expression of
|
Cxcl12
|
|
|
| 36496 |
Cxcl12
|
|
increases_activity of
|
CXCL12/CXCR4 signaling
|
|
|
| 36497 |
Cxcr4
|
|
increases_activity of
|
CXCL12/CXCR4 signaling
|
|
|
| 37259 |
Anxa2
|
|
increases_activity of
|
CXCL12/CXCR4 signaling
|
|
in vivo
|
|
21108988
|
|
3,403
|
| 31615 |
Angptl3
|
|
increases_quantity of
|
HSC (CD34-CD135-KSL)
|
in the BM
|
in vivo
|
| 31616 |
Angptl3
|
|
increases_quantity of
|
HSC (CD150+KSL)
|
in the BM
|
in vivo
|
| 31644 |
HSC (CD150+CD48-CD41-Lin-)
|
|
interacts (colocalizes) with
|
sinusoidal endothelium (MECA-32+)
|
|
in vivo
|
| 31645 |
sinusoidal endothelium (MECA-32+)
|
|
increases_quantity of
|
Angptl3
|
|
|
| 31649 |
Angptl3
|
|
decreases_expression of
|
Ikzf1
|
in LT-HSC (CD34-CD135-KSL)
|
in vivo
|
| 31650 |
HSC (CD34-CD135-KSL)
|
|
increases_expression of
|
Ikzf1
|
|
in vivo
|
| 31661 |
Ikzf1
|
|
decreases_activity of
|
Notch signaling pathway
|
in LT-HSC (CD34-CD135-KSL)
|
|
|
20959605
|
|
3,524
|
| 32824 |
Celsr2
|
|
increases_activity of
|
non-canonical Wnt signaling pathway
|
|
|
| 32831 |
Fzd8
|
|
increases_activity of
|
non-canonical Wnt signaling pathway
|
|
|
| 32849 |
HSC (LRC, CD135-KSL)
|
|
increases_expression of
|
Celsr2
|
in comparison to active HSC (non-LRC)
|
|
| 32850 |
HSC (LRC, CD135-KSL)
|
|
increases_expression of
|
Fzd8
|
in comparison to active HSC (non-LRC)
|
|
| 32860 |
HSC (LRC, CD135-KSL)
|
|
interacts (colocalizes) with
|
osteoblast (N-cadherin+)
|
|
in vivo
|
| 32940 |
Celsr2
|
|
interacts (colocalizes) with
|
Fzd8
|
at the interface between HSC (LRC, CD135-KSL) cells and N-cad+-OBs in the trabecular bone region
|
|
|
22817897
|
|
3,537
|
| 36498 |
Fzd8
|
|
decreases_quantity of
|
Ca2+
|
in LT-HSCs
|
|
|
22817897
|
|
3,583
|
| 33556 |
HSC (CD150+CD48-Lin-)
|
|
interacts (colocalizes) with
|
sinusoidal endothelium
|
|
in vivo
|
| 33563 |
HSC (CD150+CD48-Lin-)
|
|
interacts (colocalizes) with
|
perivascular cells (SCF+)
|
|
in vivo
|
| 33565 |
perivascular cell (Lepr+)
|
|
increases_quantity of
|
HSC (CD150+CD48-KSL)
|
in the bone marrow; if Scf is expressed in perivascular cells (Lepr+). Deletion of Scf from HSCs, osteoblasts and MSC (Nes+) cells has no effect on HSC maintanance.
|
in vivo
|
| 33567 |
perivascular cell (Lepr+)
|
|
increases_expression of
|
Kitl
|
|
|
| 33569 |
sinusoidal endothelium
|
|
increases_quantity of
|
HSC (CD150+CD48-KSL)
|
if Scf is expressed in endothelial cells. Deletion of Scf from HSCs, osteoblasts and MSC (Nes+) cells has no effect on HSC maintanance.
|
in vivo
|
| 35930 |
Kitl
|
|
increases_quantity of
|
HSC (CD150+CD48-KSL)
|
in the bone marrow; if Scf is expressed in perivascular cells (Lepr+). Deletion of Scf from HSCs, osteoblasts and MSC (Nes+) cells has no effect on HSC maintanance.
|
in vivo
|
| 37329 |
perivascular cell (Scf+)
|
|
increases_quantity of
|
HSC (CD150+CD48-KSL)
|
in the bone marrow; if Scf is expressed in perivascular cells (Lepr+). Deletion of Scf from HSCs, osteoblasts and MSC (Nes+) cells has no effect on HSC maintanance.
|
in vivo
|
| 37331 |
Kitl
|
|
interacts (colocalizes) with
|
Kit
|
|
|
|
22281595
|
|
3,667
|
| 35098 |
HSC (LRC)
|
|
interacts (colocalizes) with
|
sinusoidal endothelium (fibronectin+)
|
|
in vivo
|
| 35101 |
response to hypoxia
|
|
increases_quantity of
|
HSC (LRC)
|
|
in vivo
|
|
18047833
|
|
3,673
|
| 35189 |
endothelial cell (E4ORF1+)
|
|
increases_activity of
|
Notch signaling pathway
|
in LT-HSC (CD34-CD135-KSL)
|
in vitro
|
| 35191 |
endothelial cell (E4ORF1+)
|
|
interacts (colocalizes) with
|
HSC (CD34-CD135-KSL)
|
|
in vitro
|
| 35200 |
HSC (TNR.GFP+KSL)
|
|
interacts (colocalizes) with
|
sinusoidal endothelium (VE-cadherin+)
|
|
in vivo
|
| 35228 |
endothelial cell (E4ORF1+)
|
|
increases_quantity of
|
HSC (TNR.GFP+KSL)
|
HSC expansion depends on Notch signaling.
|
in vitro
|
| 35233 |
sinusoidal endothelium (VE-cadherin+)
|
|
increases_activity of
|
Notch signaling pathway
|
in HSC (TNR.GFP KSL)
|
in vivo
|
| 35234 |
HSC (TNR.GFP+KSL)
|
|
increases_activity of
|
Notch signaling pathway
|
during colocalization with sinusoidal endothelium (VE-cadherin+)
|
in vivo
|
| 37238 |
Notch signaling pathway
|
|
increases_quantity of
|
HSC (TNR.GFP+KSL)
|
|
in vitro
|
|
20207228
|
HSC